236 related articles for article (PubMed ID: 28898054)
21. In vivo and in vitro evaluation of
Zhang J; Wang Z; Liu H; Cai L; Feng Y; Zhou L; Wei H; Xie Y; Chen Y
Hell J Nucl Med; 2019; 22(2):103-110. PubMed ID: 31273351
[TBL] [Abstract][Full Text] [Related]
22. In vitro and in vivo evaluation of 177Lu- and 90Y-labeled E. coli heat-stable enterotoxin for specific targeting of uroguanylin receptors on human colon cancers.
Giblin MF; Sieckman GL; Shelton TD; Hoffman TJ; Forte LR; Volkert WA
Nucl Med Biol; 2006 May; 33(4):481-8. PubMed ID: 16720239
[TBL] [Abstract][Full Text] [Related]
23. In vitro, in silico and integrated strategies for the estimation of plasma protein binding. A review.
Lambrinidis G; Vallianatou T; Tsantili-Kakoulidou A
Adv Drug Deliv Rev; 2015 Jun; 86():27-45. PubMed ID: 25819487
[TBL] [Abstract][Full Text] [Related]
24. Preclinical pharmacokinetic, biodistribution, imaging and therapeutic efficacy of (177)Lu-Labeled glycated bombesin analogue for gastrin-releasing peptide receptor-positive prostate tumor targeting.
Lim JC; Cho EH; Kim JJ; Choi SM; Lee SY; Nam SS; Park UJ; Park SH
Nucl Med Biol; 2015 Mar; 42(3):234-41. PubMed ID: 25498002
[TBL] [Abstract][Full Text] [Related]
25. Melanoma targeting property of a Lu-177-labeled lactam bridge-cyclized alpha-MSH peptide.
Guo H; Miao Y
Bioorg Med Chem Lett; 2013 Apr; 23(8):2319-23. PubMed ID: 23473679
[TBL] [Abstract][Full Text] [Related]
26. Discovery of Glutamate Carboxypeptidase III Ligands to Compete the Uptake of [
Müller M; Lucaroni L; Favalli N; Bassi G; Neri D; Cazzamalli S; Oehler S
J Med Chem; 2024 May; 67(10):8247-8260. PubMed ID: 38716576
[TBL] [Abstract][Full Text] [Related]
27. Stability and Biodistribution of Thiol-Functionalized and (177)Lu-Labeled Metal Chelating Polymers Bound to Gold Nanoparticles.
Yook S; Lu Y; Jeong JJ; Cai Z; Tong L; Alwarda R; Pignol JP; Winnik MA; Reilly RM
Biomacromolecules; 2016 Apr; 17(4):1292-302. PubMed ID: 26974228
[TBL] [Abstract][Full Text] [Related]
28. Synthesis and biological evaluation of a novel (177)Lu-DOTA-[Gly(3)-cyclized(Dap(4), (d)-Phe(7), Asp(10))-Arg(11)]α-MSH(3-13) analogue for melanocortin-1 receptor-positive tumor targeting.
Lim JC; Hong YD; Kim JJ; Choi SM; Baek HS; Choi SJ
Cancer Biother Radiopharm; 2012 Oct; 27(8):464-72. PubMed ID: 22831553
[TBL] [Abstract][Full Text] [Related]
29. DOTA conjugate with an albumin-binding entity enables the first folic acid-targeted 177Lu-radionuclide tumor therapy in mice.
Müller C; Struthers H; Winiger C; Zhernosekov K; Schibli R
J Nucl Med; 2013 Jan; 54(1):124-31. PubMed ID: 23236020
[TBL] [Abstract][Full Text] [Related]
30. Direct in vitro and in vivo comparison of (161)Tb and (177)Lu using a tumour-targeting folate conjugate.
Müller C; Reber J; Haller S; Dorrer H; Bernhardt P; Zhernosekov K; Türler A; Schibli R
Eur J Nucl Med Mol Imaging; 2014 Mar; 41(3):476-85. PubMed ID: 24100768
[TBL] [Abstract][Full Text] [Related]
31. Radioimmunotherapy of a human lung cancer xenograft with monoclonal antibody RS7: evaluation of (177)Lu and comparison of its efficacy with that of (90)Y and residualizing (131)I.
Stein R; Govindan SV; Chen S; Reed L; Richel H; Griffiths GL; Hansen HJ; Goldenberg DM
J Nucl Med; 2001 Jun; 42(6):967-74. PubMed ID: 11390564
[TBL] [Abstract][Full Text] [Related]
32. Synthesis of
Deiser S; Drexler M; Moreno-Alcántar G; Irl M; Schmidt C; Günther T; Casini A
Inorg Chem; 2023 Dec; 62(50):20710-20720. PubMed ID: 37556427
[TBL] [Abstract][Full Text] [Related]
33. Consequences of meta-stable (177m)Lu admixture in (177)Lu for patient dosimetry.
Konijnenberg MW
Curr Radiopharm; 2015; 8(2):145-9. PubMed ID: 25771362
[TBL] [Abstract][Full Text] [Related]
34. Synthesis and evaluation of novel bifunctional chelating agents based on 1,4,7,10-tetraazacyclododecane-N,N',N",N"'-tetraacetic acid for radiolabeling proteins.
Chappell LL; Ma D; Milenic DE; Garmestani K; Venditto V; Beitzel MP; Brechbiel MW
Nucl Med Biol; 2003 Aug; 30(6):581-95. PubMed ID: 12900284
[TBL] [Abstract][Full Text] [Related]
35. (89)Zr as a PET surrogate radioisotope for scouting biodistribution of the therapeutic radiometals (90)Y and (177)Lu in tumor-bearing nude mice after coupling to the internalizing antibody cetuximab.
Perk LR; Visser GW; Vosjan MJ; Stigter-van Walsum M; Tijink BM; Leemans CR; van Dongen GA
J Nucl Med; 2005 Nov; 46(11):1898-906. PubMed ID: 16269605
[TBL] [Abstract][Full Text] [Related]
36. Combining Albumin-Binding Properties and Interaction with Pemetrexed to Improve the Tissue Distribution of Radiofolates.
Müller C; Guzik P; Siwowska K; Cohrs S; Schmid RM; Schibli R
Molecules; 2018 Jun; 23(6):. PubMed ID: 29914162
[TBL] [Abstract][Full Text] [Related]
37. Preparation and biological evaluation of 111In-, 177Lu- and 90Y-labeled DOTA analogues conjugated to B72.3.
Mohsin H; Fitzsimmons J; Shelton T; Hoffman TJ; Cutler CS; Lewis MR; Athey PS; Gulyas G; Kiefer GE; Frank RK; Simon J; Lever SZ; Jurisson SS
Nucl Med Biol; 2007 Jul; 34(5):493-502. PubMed ID: 17591549
[TBL] [Abstract][Full Text] [Related]
38. Novel Structural Modification Based on Evans Blue Dye to Improve Pharmacokinetics of a Somastostatin-Receptor-Based Theranostic Agent.
Bandara N; Jacobson O; Mpoy C; Chen X; Rogers BE
Bioconjug Chem; 2018 Jul; 29(7):2448-2454. PubMed ID: 29927587
[TBL] [Abstract][Full Text] [Related]
39. Preclinical Investigations to Explore the Difference between the Diastereomers [
Borgna F; Deberle LM; Busslinger SD; Tschan VJ; Walde LM; Becker AE; Schibli R; Müller C
Mol Pharm; 2022 Jul; 19(7):2105-2114. PubMed ID: 35544699
[TBL] [Abstract][Full Text] [Related]
40. In vivo evaluation of pretargeted 64Cu for tumor imaging and therapy.
Lewis MR; Wang M; Axworthy DB; Theodore LJ; Mallet RW; Fritzberg AR; Welch MJ; Anderson CJ
J Nucl Med; 2003 Aug; 44(8):1284-92. PubMed ID: 12902420
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]